Evidence map›Paper›PMID 34350827›Full record

ArticleeLife2021

Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy.

Sierra M Barone, Alberta Ga Paul, Lyndsey M Muehling, Joanne A Lannigan, William W Kwok, Ronald B Turner, Judith A Woodfolk, Jonathan M Irish

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. CD3bioRxiv : the preprint server for biology · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sierra M Barone *Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States.ORCID 0000-0001-5944-750X
Alberta Ga Paul *Allergy Division, Department of Medicine, University of Virginia School of Medicine, Charlottesville, United States.ORCID 0000-0002-9318-3760
Lyndsey M Muehling *Allergy Division, Department of Medicine, University of Virginia School of Medicine, Charlottesville, United States.ORCID 0000-0003-3203-3264
Joanne A LanniganDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, United States.ORCID 0000-0002-3981-8681
William W KwokBenaroya Research Institute at Virginia Mason, Seattle, United States.ORCID 0000-0003-4843-4599
Ronald B TurnerDepartment of Pediatrics, University of Virginia School of Medicine, Charlottesville, United States.
Judith A WoodfolkAllergy Division, Department of Medicine, University of Virginia School of Medicine, Charlottesville, United States.ORCID 0000-0002-8915-4334
Jonathan M IrishDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, United States.ORCID 0000-0001-9428-8866
University of Virginia · USVanderbilt University · USBenaroya Research Institute

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Single-Cell Biology and Data Analysis Shared Resource (SCB-DA SR)U54CA217450 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$8.5M
Single Cell Methods for Bioeffector Discovery and AnalysisR01CA226833 · NCI · VANDERBILT UNIVERSITY · PI BRIAN O BACHMANN, Jonathan Michael Irish · 2019 to 2026
$6.1M
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in HumansU01AI125056 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2016 to 2020
$4.1M
BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational DiscoveryU01TR002625 · NCATS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI PORCO, JOHN A. · 2020 to 2023
$2.7M
Regulation of extracellular vesicle biogenesis through cell adhesionR01CA249424 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PUA, HEATHER H, WEAVER, ALISSA M · 2020 to 2025
$2.6M
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and DiseaseR21AI160334 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2021 to 2022
$444k
Exploring Amplified Th1 Responses and a Role for the IgE/Interferon Axis in Allergic Asthmatics Infected with RhinovirusR21AI138077 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2019 to 2020
$437k
NCATS NIH HHS U01 TR002625NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA226833NCI NIH HHS R01 CA249424NCI NIH HHS U54 CA217450NIAID NIH HHS R21 AI138077NIAID NIH HHS R21 AI160334NIAID NIH HHS T32 AI007496NIAID NIH HHS U01 AI125056NIH HHS R01 CA226833NIH HHS R21 AI138077NIH HHS T32 AI007496NIH HHS U01 AI125056NIH HHS U01 TR002625NIH HHS U54 CA217450
6 · The paper itself

Abstract

For an emerging disease like COVID-19, systems immunology tools may quickly identify and quantitatively characterize cells associated with disease progression or clinical response. With repeated sampling, immune monitoring creates a real-time portrait of the cells reacting to a novel virus before disease-specific knowledge and tools are established. However, single cell analysis tools can struggle to reveal rare cells that are under 0.1% of the population. Here, the machine learning workflow Tracking Responders EXpanding (T-REX) was created to identify changes in both rare and common cells across human immune monitoring settings. T-REX identified cells with highly similar phenotypes that localized to hotspots of significant change during rhinovirus and SARS-CoV-2 infections. Specialized MHCII tetramer reagents that mark rhinovirus-specific CD4+ cells were left out during analysis and then used to test whether T-REX identified biologically significant cells. T-REX identified rhinovirus-specific CD4+ T cells based on phenotypically homogeneous cells expanding by ≥95% following infection. T-REX successfully identified hotspots of virus-specific T cells by comparing infection (day 7) to either pre-infection (day 0) or post-infection (day 28) samples. Plotting the direction and degree of change for each individual donor provided a useful summary view and revealed patterns of immune system behavior across immune monitoring settings. For example, the magnitude and direction of change in some COVID-19 patients was comparable to blast crisis acute myeloid leukemia patients undergoing a complete response to chemotherapy. Other COVID-19 patients instead displayed an immune trajectory like that seen in rhinovirus infection or checkpoint inhibitor therapy for melanoma. The T-REX algorithm thus rapidly identifies and characterizes mechanistically significant cells and places emerging diseases into a systems immunology context for comparison to well-studied immune changes.

Indexed as

Unsupervised Machine LearningAdolescentAdultAlgorithmsCD4-Positive T-LymphocytesCOVID-19HumansLeukemia, Myeloid, AcuteMelanomaNeoplasmsPicornaviridae InfectionsRhinovirusSARS-CoV-2Young Adultcomputational biologyCOVID-19cytometryhumanimmune monitoringimmunologyinflammationmachine learningrhinovirussystems biology

Identifiers

PMID34350827
PMCPMC8370768
OpenAlexW3193259280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.